Last updated on January 2019

A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation


Brief description of study

To investigate the safety and pharmacokinetics of apixaban in children with congenital or acquired heart disease who have a need for anticoagulation.

Clinical Study Identifier: NCT02981472

Contact Investigators or Research Sites near you

Start Over

Local Institution

Phoenix, AZ United States
  Connect »

Riley Hospital For Children

Indianapolis, IN United States
  Connect »

Boston Childrens Hospital

Boston, MA United States
  Connect »

University Of Michigan

Ann Arbor, MI United States
  Connect »

Childrens Hospital Of Philadelphia

Philadelphia, PA United States
  Connect »

Texas Children'S Hospital

Houston, TX United States
  Connect »

Primary Children's Hospital

Salt Lake City, UT United States
  Connect »

Local Institution

Westmead, Australia
  Connect »

Local Institution

Parkville, Australia
  Connect »

Local Institution

Passo Fundo, Brazil
  Connect »

Local Institution

Porto Alegre, Brazil
  Connect »

Local Institution

Montpellier, France
  Connect »

Local Institution

Petach Tikva, Israel
  Connect »

Local Institution

Tel Hashomer, Israel
  Connect »

Local Institution

Mexico City, Mexico
  Connect »

Local Institution

Leicester, United Kingdom
  Connect »

Local Institution

Bristol, United Kingdom
  Connect »

Local Institution

Manchester, United Kingdom
  Connect »

Local Institution

Ekaterinburg, Russian Federation
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.